PL2631654T3 - Oznaczenie uwalniania neuropeptydu dla kanałów sodowych - Google Patents

Oznaczenie uwalniania neuropeptydu dla kanałów sodowych

Info

Publication number
PL2631654T3
PL2631654T3 PL13169122T PL13169122T PL2631654T3 PL 2631654 T3 PL2631654 T3 PL 2631654T3 PL 13169122 T PL13169122 T PL 13169122T PL 13169122 T PL13169122 T PL 13169122T PL 2631654 T3 PL2631654 T3 PL 2631654T3
Authority
PL
Poland
Prior art keywords
release assay
sodium channels
neuropeptide release
neuropeptide
channels
Prior art date
Application number
PL13169122T
Other languages
English (en)
Inventor
Haber Nicole M Alessandri
Lynn Macdonald
Michael L Lacroix-Fralish
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/155,491 external-priority patent/US8871996B2/en
Priority claimed from US13/236,117 external-priority patent/US8486647B2/en
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PL2631654T3 publication Critical patent/PL2631654T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL13169122T 2011-05-12 2012-05-07 Oznaczenie uwalniania neuropeptydu dla kanałów sodowych PL2631654T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161485488P 2011-05-12 2011-05-12
US13/155,491 US8871996B2 (en) 2010-06-09 2011-06-08 Mice expressing human voltage-gated sodium channels
US13/236,117 US8486647B2 (en) 2010-06-09 2011-09-19 Neuropeptide release assay for sodium channels
EP12167014.5A EP2527842B1 (en) 2011-05-12 2012-05-07 Neuropeptide release assay for sodium channels
EP13169122.2A EP2631654B1 (en) 2011-05-12 2012-05-07 Neuropeptide release assay for sodium channels

Publications (1)

Publication Number Publication Date
PL2631654T3 true PL2631654T3 (pl) 2015-09-30

Family

ID=46045997

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13169122T PL2631654T3 (pl) 2011-05-12 2012-05-07 Oznaczenie uwalniania neuropeptydu dla kanałów sodowych

Country Status (6)

Country Link
EP (3) EP2579039B1 (pl)
CY (1) CY1116625T1 (pl)
DK (2) DK2527842T3 (pl)
ES (2) ES2541535T3 (pl)
PL (1) PL2631654T3 (pl)
PT (1) PT2631654E (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105189553A (zh) 2013-03-14 2015-12-23 瑞泽恩制药公司 Nav1.7的人抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
US20090298095A1 (en) 2005-04-15 2009-12-03 The John Hopkins University Immortalization of cells including neuronal cells
WO2007109324A2 (en) * 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Potent and selective nav 1.7 sodium channel blockers
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
EP2262898B1 (en) 2008-03-07 2018-01-24 Regeneron Pharmaceuticals, Inc. Es cell-derived mice from diploid host embryo injection
CA2751159A1 (en) * 2009-02-02 2010-08-05 Chromocell Corporation Cell lines expressing nav and methods of using them

Also Published As

Publication number Publication date
EP2527842A1 (en) 2012-11-28
ES2656852T3 (es) 2018-02-28
EP2527842B1 (en) 2013-06-05
EP2631654B1 (en) 2015-04-15
HK1185943A1 (en) 2014-02-28
PT2631654E (pt) 2015-08-21
DK2631654T3 (en) 2015-07-20
ES2541535T3 (es) 2015-07-21
EP2631654A1 (en) 2013-08-28
DK2527842T3 (da) 2013-09-08
CY1116625T1 (el) 2017-03-15
HK1174387A1 (en) 2013-06-07
EP2579039A1 (en) 2013-04-10
EP2579039B1 (en) 2017-10-25

Similar Documents

Publication Publication Date Title
IL286152A (en) Modified imidazopyridinyl-aminopyridine compounds
GB201108678D0 (en) Multiplexed proximity ligation assay
GB201106395D0 (en) Compounds
GB201109763D0 (en) Compounds
PL2572204T3 (pl) Odczynnik do uwalniania dla związków witaminy d
DK2783152T3 (da) Trykafgivelsessystem
IL228609A0 (en) Sustained release silver compound for water purification
GB201107197D0 (en) Compounds
SG11201402196YA (en) Release reagent for vitamin d compounds
PL2766541T3 (pl) Człon łączący do rusztowań
PL2729809T3 (pl) Test oznaczający
EP2687374A4 (en) INTERFACE
GB201110938D0 (en) Compounds
GB201106615D0 (en) Assay
GB201105659D0 (en) Compounds
GB201102659D0 (en) Assay
PL2631654T3 (pl) Oznaczenie uwalniania neuropeptydu dla kanałów sodowych
GB201121265D0 (en) Assay
GB201113101D0 (en) Assay
GB201118613D0 (en) Compounds
HUP1100207A2 (en) Modified release composition
GB201102162D0 (en) Contraceptive compounds
GB201107431D0 (en) Assay
GB201117309D0 (en) Assay
GB201111698D0 (en) Assay